Arsanis Inc. priced its initial public offering at $10 late Wednesday, well below its $15 to $17 price range. The clinical-stage biotech sold 4 million shares to raise $40 million. Underwriters have the option to buy up to 600,000 additional shares at the offer price to cover over-allotments. The shares are expected to start trading later Thursday on Nasdaq, under the ticker symbol “ASNS”.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News